Should I buy or sell Pliant Therapeutics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PLRX shares. View PLRX analyst ratings or view top-rated stocks .

What is Pliant Therapeutics' stock price target for 2024?

10 brokerages have issued 1 year price objectives for Pliant Therapeutics' stock. Their PLRX share price targets range from $36.00 to $63.00. On average, they predict the company's share price to reach $45.67 in the next year. This suggests a possible upside of 227.4% from the stock's current price. View analysts price targets for PLRX or view top-rated stocks among Wall Street analysts .

How have PLRX shares performed in 2024?

Pliant Therapeutics' stock was trading at $18.11 at the start of the year. Since then, PLRX stock has decreased by 23.0% and is now trading at $13.95. View the best growth stocks for 2024 here .

When is Pliant Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our PLRX earnings forecast .

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) issued its earnings results on Tuesday, November, 9th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by $0.06. The company had revenue of $1.61 million for the quarter, compared to the consensus estimate of $2.50 million.

What ETFs hold Pliant Therapeutics' stock?

ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) . iShares U.S. Pharmaceuticals ETF (IHE) .

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE) , CrowdStrike (CRWD) , Trevena (TRVN) , AbbVie (ABBV) , Abbott Laboratories (ABT) , Archer-Daniels-Midland (ADM) , Akero Therapeutics (AKRO) , Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN) .

When did Pliant Therapeutics IPO?

Pliant Therapeutics (PLRX) raised $90 million in an initial public offering (IPO) on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Pliant Therapeutics' major shareholders?

Pliant Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Mass General Brigham Inc (0.48%), Russell Investments Group Ltd. (0.08%), HighMark Wealth Management LLC (0.07%), ProShare Advisors LLC (0.02%), China Universal Asset Management Co. Ltd. (0.02%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Bernard Coulie , Eric Lefebvre , Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette. View institutional ownership trends .

How do I buy shares of Pliant Therapeutics?

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:PLRX

Pliant Therapeutics (PLRX) Stock Price, News & Analysis

→ Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad)

Free PLRX Stock Alerts

$13.95

+0.54 (+4.03%)

(As of 02:13 PM ET)

Compare

Today's Range: $13.29
▼
$14.10
50-Day Range: $11.81
▼
$16.54
52-Week Range: $11.21
▼
$24.74

Volume: 209,977 shs
Average Volume: 380,233 shs
Market Capitalization: $841.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $45.67

Get Pliant Therapeutics alerts:

Pliant Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 227.4% Upside
$45.67 Price Target
Short Interest: Bearish
12.63% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 0.04
Based on 26 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.27) to ($3.54) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.87 out of 5 stars

Medical Sector

204th out of 915 stocks

Pharmaceutical Preparations Industry

82nd out of 426 stocks

4.5

Analyst's Opinion

Consensus Rating
Pliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Pliant Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about Pliant Therapeutics' stock forecast and price target.

0.0

Short Interest

Percentage of Shares Shorted
12.63% of the outstanding shares of Pliant Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Pliant Therapeutics has a short interest ratio ("days to cover") of 21.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Pliant Therapeutics has recently increased by 2.14%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Pliant Therapeutics does not currently pay a dividend.
Dividend Growth
Pliant Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pliant Therapeutics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Pliant Therapeutics is -0.73.

1.7

News and Social Media Coverage

News Sentiment
Pliant Therapeutics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 26 news articles for Pliant Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 4 people have searched for PLRX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.60% of the stock of Pliant Therapeutics is held by insiders.
Percentage Held by Institutions
97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Pliant Therapeutics' insider trading history.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Pliant Therapeutics are expected to decrease in the coming year, from ($3.27) to ($3.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pliant Therapeutics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pliant Therapeutics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pliant Therapeutics has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
Read more about Pliant Therapeutics' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad American Hartford Gold Group

Trump Asset Seizure Threat Alert: Could Your Savings Be Next?

Trump Asset Seizures Threat A Warning For 401K Owners?

Request Your FREE WEALTH PROTECTION GUIDE

About Pliant Therapeutics Stock (NASDAQ:PLRX)

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.